Stock Ratings / Health Care / KURA / forecast

AKTS (56) ORIC (39) CYRX (38) ANRO (38) ⌘ Pro Terminal →

Kura Oncology Inc. (KURA) 12-Month Stock Forecast & Price Target Cone

$10.56 -1.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Kura Oncology Inc. (KURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $939.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KURA)Realized 20D OHLCV Swing Band: ±11.2%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your KURA Position Size: $10,000

Shares at $10.56: 947.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $7.16

$6,780

$-3,220 (-32.2%)

12M Consensus BaseTarget $9.18

$8,693

$-1,307 (-13.1%)

12M Bull Case BreakoutTarget $14.60

$13,826

+$3,826 (+38.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$10	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$14	69%	B
JP MorganUS Large-Cap Research	SELL	$8	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KURA)

✓Walkthrough of KURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.59%📐 HORIZONTAL RANGE

2026-10-30O $10.50H $10.75L $9.93C $10.56VOL 2.25M

RES: $15.65SUP: $8.95SMA50: $11.15SMA200: $9.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KURA Butterfly Map → + Track KURA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KURA)

Health Care Rank #952 of 1016 ⚔️ AKTS vs KURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KURA vs. AKTS, ORIC, CYRX, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kura Oncology Inc. (KURA) ranks #952 by composite RQD confidence (29/100, grade E) and #368 by equity capitalization ($939.4M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with KURA at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KURA ACTIVE Kura Oncology Inc.	E	29/100	—	—	-35.0%	-1.49%	$939.4M	Benchmark Subject
AKTS Aktis Oncology Inc.	D+	56/100	—	—	—	+0.18%	$937.2M	/akts-vs-kura →
ORIC Oric Pharmaceuticals Inc.	D-	39/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-kura →
CYRX CryoPort Inc.	D-	38/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-kura →
ANRO Alto Neuroscience Inc.	D-	38/100	—	—	-35.0%	+0.60%	$921.0M	/anro-vs-kura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001422143

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kura Oncology Inc. (KURA) reported GAAP revenue of $67.5M (+25.2% vs. FY2024 revenue of $53.9M ) , GAAP net income of -$278.7M, operating cash flow of -$64.1M, and free cash flow of -$70.7M (-152.8% YoY). On the balance sheet, KURA closed FY2025 with $738.4M in total assets against $9.7M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$67.5M	-$278.7M	-$64.1M	-$70.7M	$738.4M	$9.7M
FY2024 (FY)	2024-12-31	$53.9M	-$174.0M	$134.3M	$133.8M	$760.2M	$6.9M
FY2023 (FY)	2023-12-31	$0	-$152.6M	-$124.8M	-$124.8M	—	—

3. KURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kura Oncology Inc. (NASDAQ: KURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $10.56 (-1.49% 1D, market cap $939.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KURA ranks #952 in composite RQD confidence.

How does KURA compare to AKTS and ORIC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AKTS (Aktis Oncology Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $937.2M) and ORIC (Oric Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KURA?

Per KURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422143), Kura Oncology Inc. generated $67.5M in revenue (+25.2% YoY), -$278.7M in net income, and -$70.7M in free cash flow against $738.4M in total assets and $9.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KURA trading relative to its 50-day, 200-day, and 52-week technical levels?

KURA last traded at $10.56 (-1.49% on volume of 1,590,517 shares), positioning the stock -5.29% below its 50-day simple moving average ($11.15) and +7.65% above its 200-day simple moving average ($9.81). Across its 52-week range of $7.36 to $13.90, KURA sits at the 48.9% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($9.38 to $11.74).

KURA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is KURA's 12-month stock price target?

Kura Oncology Inc. (KURA) carries a 12-month consensus base price target of $9.18 (-13.1% from $10.56), with a bull-case target of $14.6 and a bear-case floor of $7.16.